Treace Medical Q1 revenue falls 10% to $47.2 million; net loss widens to $18.0 million
Treace Medical Concepts reported first quarter 2026 revenue of $47.2 million, down 10% from $52.6 million a year earlier, and a net loss of $18.0 million, or $0.28 per share, compared with $15.9 million, or $0.25 per share, in the first quarter of 2025. The company reaffirmed its full-year 2026 revenue guidance of $202 million to $212 million, a decline of 5% to 0%, so shareholders face weaker sales and a wider loss this quarter, though the outlook was not cut.
Key points
- First quarter 2026 revenue was $47.2 million, down 10% from $52.6 million in the first quarter of 2025.
- Net loss was $18.0 million, or $0.28 per share, versus $15.9 million, or $0.25 per share, a year earlier.
- Full-year 2026 revenue guidance of $202 million to $212 million was reaffirmed, with an Adjusted EBITDA loss expected in the range of $4.0 million to $6.0 million.
- Cash, cash equivalents and marketable securities totaled $51.9 million as of March 31, 2026, and the credit facility provides an additional $115 million subject to conditions.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.